Literature DB >> 12209679

Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.

Geza Acs1, Paul J Zhang, Timothy R Rebbeck, Peter Acs, Ajay Verma.   

Abstract

BACKGROUND: Erythropoietin (Epo), induced by hypoxia, controls the survival, proliferation, and differentiation of Epo receptor (EpoR)-bearing erythroid progenitors and plays a role in the protection of neurons from hypoxic damage. Hypoxia in malignant disease is associated with invasion, metastasis, resistance to therapy, and selection for cells with diminished apoptotic potential. The authors recently demonstrated the basal and hypoxia-stimulated expression of Epo and EpoR in human breast carcinoma cell lines and in breast carcinomas, suggesting a role for autocrine Epo signaling in the hypoxic adaptations of mammary neoplasms.
METHODS: The authors characterized the expression of Epo and EpoR by immunohistochemistry in 184 invasive mammary carcinomas and 158 in situ mammary carcinomas and benign mammary epithelium. They analyzed the correlation of Epo and EpoR immunostaining with clinicopathologic tumor features and the patients' smoking history.
RESULTS: Benign mammary epithelial cells showed weak-to-moderate expression of Epo and EpoR. EpoR immunostaining was increased in carcinomas compared with benign epithelium both in nonsmokers and smokers, and Epo immunostaining was increased in carcinomas compared with benign epithelium in nonsmokers but not in smokers. Prominent Epo staining was seen in tumor cells adjacent to necrotic areas and at the infiltrating edge of tumors. EpoR staining, but not Epo staining, was significantly greater in tumors that showed high histologic grade, tumor necrosis, lymphovascular invasion, lymph node metastases, and loss of hormone receptor expression.
CONCLUSIONS: The current findings suggest that increased EpoR expression may play an important role in breast carcinogenesis. The induction of autocrine or paracrine Epo signaling may represent a novel mechanism by which hypoxia can promote breast carcinoma. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209679     DOI: 10.1002/cncr.10787

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.

Authors:  M Kondyli; G Gatzounis; A Kyritsis; J Varakis; M Assimakopoulou
Journal:  J Neurooncol       Date:  2010-03-25       Impact factor: 4.130

2.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma.

Authors:  Gou Yamamoto; Tarou Irie; Tadateru Aida; Yuuki Nagoshi; Reiko Tsuchiya; Tetsuhiko Tachikawa
Journal:  Virchows Arch       Date:  2006-01-14       Impact factor: 4.064

4.  Detection of deregulated pathways to lymphatic metastasis in oral squamous cell carcinoma.

Authors:  Eryang Zhao; Jiankai Xu; Xiaodong Yin; Yu Sun; Jinna Shi; Xia Li
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

Review 5.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  EPO improves the proliferation and inhibits apoptosis of trophoblast and decidual stromal cells through activating STAT-5 and inactivating p38 signal in human early pregnancy.

Authors:  Yu Qing Ji; Yu Quan Zhang; Ming Qing Li; Mei Rong Du; Wei Wei Wei; Da Jin Li
Journal:  Int J Clin Exp Pathol       Date:  2011-11-03

7.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

9.  Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.

Authors:  M Aapro; B Osterwalder; A Scherhag; H U Burger
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R.

Authors:  N D Seibold; S E Schild; M P Gebhard; F Noack; U Schröder; D Rades
Journal:  Strahlenther Onkol       Date:  2013-05-24       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.